Heparin Thromboprophylaxis in Medical-Surgical Critically Ill Patients: A Systematic Review and Meta-Analysis of Randomized Trials*

Objective:Venous thromboembolism prevention during critical illness is a widely used quality metric. The objective of this systematic review was to systematically review the efficacy and safety of heparin thromboprophylaxis in medical-surgical patients in the ICU. Data Sources:We searched EMBASE, MEDLINE, the Cochrane Controlled Trials Register, Clinicaltrials.gov, and personal files through May 2012. Study Selection:Randomized trials in adult medical-surgical ICU patients comparing any heparin (unfractionated heparin or low-molecular-weight heparin) with each other or no anticoagulant prophylaxis, evaluating deep vein thrombosis, pulmonary embolism, major bleeding, or mortality. Data Extraction:Independently, in duplicate, we abstracted trial characteristics, outcomes, and risk of bias. Data Synthesis:Seven trials involved 7,226 patients. Any heparin thromboprophylaxis compared with placebo reduced rates of deep vein thrombosis (pooled risk ratio, 0.51 [95% CI, 0.41, 0.63]; p < 0.0001; I2 = 77%) and pulmonary embolism (risk ratio, 0.52 [95% CI, 0.28, 0.97]; p = 0.04; I2 = 0%) but not symptomatic deep vein thrombosis (risk ratio, 0.86 [95% CI, 0.59, 1.25]; p = 0.43). Major bleeding (risk ratio, 0.82 [95% CI, 0.56, 1.21]; p = 0.32; I2 = 50%) and mortality (risk ratio, 0.89 [95% CI, 0.78, 1.02]; p = 0.09; I2 = 0%) rates were similar. Compared with unfractionated heparin, low-molecular-weight heparin reduced rates of pulmonary embolism (risk ratio, 0.62 [95% CI, 0.39, 1.00]; p = 0.05; I2 = 53%) and symptomatic pulmonary embolism (risk ratio, 0.58 [95% CI, 0.34, 0.97]; p = 0.04) but not deep vein thrombosis (risk ratio, 0.90 [95% CI, 0.74, 1.08]; p = 0.26; I2 = 0%), symptomatic deep vein thrombosis (risk ratio, 0.87 [95% CI, 0.60, 1.25]; p = 0.44; I2 = 0%), major bleeding (risk ratio, 0.97 [95% CI, 0.75, 1.26]; p = 0.83; I2 = 0%), or mortality (risk ratio, 0.93 [95% CI, 0.82, 1.04]; p = 0.20; I2 = 31%). Conclusions:Trial evidence to date suggests that any type of heparin thromboprophylaxis decreases deep vein thrombosis and pulmonary embolism in medical-surgical critically ill patients, and low-molecular-weight heparin compared with bid unfractionated heparin decreases pulmonary embolism and symptomatic pulmonary embolism. Major bleeding and mortality rates do not appear to be significantly influenced by heparin thromboprophylaxis in the ICU setting. Trial methodology, indirectness, and the heterogeneity and imprecision of some results temper inferences from this literature.

[1]  G. Guyatt,et al.  ANTITHROMBOTIC THERAPY AND PREVENTION OF THROMBOSIS, 9TH ED: ACCP GUIDELINES , 2012 .

[2]  Timothy J Wilt,et al.  Venous Thromboembolism Prophylaxis in Hospitalized Medical Patients and Those With Stroke: A Background Review for an American College of Physicians Clinical Practice Guideline , 2011, Annals of Internal Medicine.

[3]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[4]  D. Cook,et al.  Dosing frequency of unfractionated heparin thromboprophylaxis: a meta-analysis. , 2011, Chest.

[5]  G. Guyatt,et al.  Dalteparin versus unfractionated heparin in critically ill patients. , 2011, The New England journal of medicine.

[6]  C. Bias.  The Cochrane Collaboration's tool for assessing risk of bias in randomised trials , 2011 .

[7]  D. Moher,et al.  Chapter 10: Addressing reporting biases , 2011 .

[8]  J. Slattery,et al.  Thigh-Length Versus Below-Knee Stockings for Deep Venous Thrombosis Prophylaxis After Stroke , 2010, Annals of Internal Medicine.

[9]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[10]  N. K. Pandey,et al.  Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery , 2010, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[11]  P. Sandercock,et al.  Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial , 2009, The Lancet.

[12]  D. Cook,et al.  Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review. , 2009, Journal of critical care.

[13]  WRITING COMMITTEE , 2009 .

[14]  Larry V. Hedges,et al.  Fixed‐Effect Versus Random‐Effects Models , 2009, Introduction to Meta‐Analysis.

[15]  A. Shorr,et al.  Venous thromboembolism in critically ill patients , 2008, Thrombosis and Haemostasis.

[16]  A. Nicolaides,et al.  Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism in high-risk patients. , 2008, The Cochrane database of systematic reviews.

[17]  D. Hoppensteadt,et al.  Are All Low Molecular Weight Heparins Equivalent in the Management of Venous Thromboembolism? , 2008, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[18]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[19]  Massimo Antonelli,et al.  Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). , 2007, American journal of respiratory and critical care medicine.

[20]  D. Cook,et al.  Bleeding during critical illness: a prospective cohort study using a new measurement tool. , 2007, Clinical and investigative medicine. Medecine clinique et experimentale.

[21]  J. Douketis,et al.  Meta-analysis: Anticoagulant Prophylaxis to Prevent Symptomatic Venous Thromboembolism in Hospitalized Medical Patients , 2007, Annals of Internal Medicine.

[22]  W. Chaboyer,et al.  Mechanical thromboprophylaxis in critically ill patients: a systematic review and meta-analysis. , 2006, American journal of critical care : an official publication, American Association of Critical-Care Nurses.

[23]  G. Guyatt,et al.  Deep venous thrombosis: clinically silent in the intensive care unit. , 2005, Journal of critical care.

[24]  G. Guyatt,et al.  Clinically important deep vein thrombosis in the intensive care unit: a survey of intensivists , 2004, Critical care.

[25]  G. Nenci,et al.  Low molecular weight heparins: are they interchangeable? No , 2003, Journal of thrombosis and haemostasis : JTH.

[26]  P. Prandoni,et al.  Low molecular weight heparins: are they interchangeable? Yes , 2002, Journal of thrombosis and haemostasis : JTH.

[27]  D. Cook,et al.  Venous thromboembolism and its prevention in critical care. , 2002, Journal of critical care.

[28]  S. Laporte,et al.  Meta‐analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery , 2001, The British journal of surgery.

[29]  D. Cook,et al.  Deep vein thrombosis and its prevention in critically ill adults. , 2001, Archives of internal medicine.

[30]  S. Ziegler,et al.  Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis: meta-analysis based on original patient data. , 2001, Thrombosis research.

[31]  S. Goldhaber,et al.  Low molecular weight heparin versus minidose unfractionated heparin for prophylaxis against venous thromboembolism in Medical Intensive Care Unit patients A randomized controlled trial , 2000 .

[32]  M. Prins,et al.  Low-Molecular-Weight Heparins: Are They Interchangeable? , 2000, Pathophysiology of Haemostasis and Thrombosis.

[33]  D. Warwick,et al.  The contrast between venographic and clinical endpoints in trials of thromboprophylaxis in hip replacement. , 2000, The Journal of bone and joint surgery. British volume.

[34]  R. Pordes,et al.  Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. , 2000, American journal of respiratory and critical care medicine.

[35]  Y. Kupfer,et al.  Subcutaneous Heparin Prophylaxis Significantly Reduces The Incidence Of Venous Thromboembolic Events In The Critically Ill , 1999 .

[36]  E. Hoffman,et al.  Interstitial lung disease: A quantitative study using the adaptive multiple feature method. , 1999, American journal of respiratory and critical care medicine.

[37]  S. Goldhaber.  Venous thromboembolism in the intensive care unit: the last frontier for prophylaxis. , 1998, Chest.

[38]  S. Yusuf,et al.  Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. , 1997, Controlled clinical trials.

[39]  E. Ingenito,et al.  Prevalence of deep venous thrombosis among patients in medical intensive care. , 1996, JAMA.

[40]  J. Heit,et al.  Prevention of venous thromboembolism. , 1995, Chest.

[41]  J. Cade.  High risk of the critically ill for venous thromboembolism , 1982, Critical care medicine.

[42]  R. Spragg,et al.  Deep venous thrombosis and pulmonary embolism. Frequency in a respiratory intensive care unit. , 1981, JAMA.